AAAAAA
Results:
1-14
|
Results: 14
Authors:
Kramar, A
Faraggi, D
Fortune, A
Reiser, B
Citation: A. Kramar et al., mROC: a computer program for combining tumour markers in predicting disease states, COMPUT M PR, 66(2-3), 2001, pp. 199-207
Authors:
Faraggi, D
Kramar, A
Citation: D. Faraggi et A. Kramar, Methodological issues associated with tumor marker development - Biostatistical aspects, UROL ONCOL, 5(5), 2000, pp. 211-213
Authors:
Ychou, M
Duffour, J
Kramar, A
Gourgou, S
Grenier, J
Citation: M. Ychou et al., Clinical significance and prognostic value of CA72-4 compared with CEA andCA19-9 in patients with gastric cancer, DIS MARKER, 16(3-4), 2000, pp. 105-110
Authors:
Lamy, PJ
Grenier, J
Kramar, A
Pujol, JL
Citation: Pj. Lamy et al., Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer, LUNG CANC, 29(3), 2000, pp. 197-203
Authors:
Cuny, M
Kramar, A
Courjal, F
Johannsdottir, V
Iacopetta, B
Fontaine, H
Grenier, J
Culine, S
Theillet, C
Citation: M. Cuny et al., Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and ofp53 mutations, CANCER RES, 60(4), 2000, pp. 1077-1083
Authors:
Simony-Lafontaine, J
Esslimani, M
Bribes, E
Gourgou, S
Lequeux, N
Lavail, R
Grenier, J
Kramar, A
Casellas, P
Citation: J. Simony-lafontaine et al., Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors, BR J CANC, 82(12), 2000, pp. 1958-1966
Authors:
Baranzelli, MC
Kramar, A
Bouffet, E
Quintana, E
Rubie, H
Edan, C
Patte, C
Citation: Mc. Baranzelli et al., Prognostic factors in children with localized malignant nonseminomatous germ cell tumors, J CL ONCOL, 17(4), 1999, pp. 1212-1218
Authors:
Kramar, A
Faraggi, D
Ychou, M
Reiser, B
Grenier, J
Citation: A. Kramar et al., The generalized ROC criterion for the evaluation of several tumor markers, REV EPIDEM, 47(4), 1999, pp. 376-383
Authors:
Kramar, A
Lebecq, A
Candalh, E
Citation: A. Kramar et al., Continual reassessment methods in phase I trials of the combination of twodrugs in oncology, STAT MED, 18(14), 1999, pp. 1849-1864
Authors:
Ychou, M
Duffour, J
Pinguet, F
Kramar, A
Joulia, JM
Topart, D
Bressolle, F
Citation: M. Ychou et al., Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: A feasibility study in patients with advanced colorectal cancer, ANTICANC R, 19(3B), 1999, pp. 2229-2235
Authors:
Lambin, P
Kramar, A
Haie-Meder, C
Gerbaulet, A
Citation: P. Lambin et al., Tumor size in cervix cancer and metastases, RADIOTH ONC, 51(1), 1999, pp. 95-96
Authors:
Culine, S
Kramar, A
Droz, JP
Theodore, C
Citation: S. Culine et al., Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer, J UROL, 161(1), 1999, pp. 173-175
Authors:
Lambin, P
Kramar, A
Haie-Meder, C
Castaigne, D
Scalliet, P
Bouzy, J
Malaise, EP
Gerbaulet, A
Citation: P. Lambin et al., Tumour size in cancer of the cervix, ACTA ONCOL, 37(7-8), 1998, pp. 729-734
Authors:
Culine, S
Bekradda, M
Kramar, A
Rey, A
Escudier, B
Droz, JP
Citation: S. Culine et al., Prognostic factors for survival in patients with brain metastases from renal cell carcinoma, CANCER, 83(12), 1998, pp. 2548-2553
Risultati:
1-14
|